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SUMMARY
The Intensive Supportive Care plus Immunosuppression 
in IgA Nephropathy (STOP-IgAN) trial was designed to 
investigate the outcomes of immunosuppressive therapy, 
when added to maximal supportive care, in patients with 
IgA nephropathy (IgAN). This was a multicentre, open-
label, randomised, controlled trial with a two-group, 
parallel group design. 
Following screening, 337 participants were recruited 
from 32 nephrology centres across Germany. The main 
inclusion criteria were biopsy confirmed primary IgAN, 
age 18–70 and a proteinuria level above 0.75 g/day plus 
hypertension, impaired renal function (estimated 
glomerular filtration rate [eGFR] <90 ml/min/1.73m2), or 
both. Patients with eGFR <30 ml/minute/1.73 m2, those 
with rapidly progressive crescentic IgAN, secondary 
IgAN and other chronic renal diseases, or who had 
previously received immunosuppression were excluded. 
The first stage of the trial involved a six-month run-in 
phase where all patients received intensive supportive 
care including renin angiotensin system (RAS) blockade 
to lower blood pressure (BP) to a target below 125/70 
mmHg. If proteinuria persisted above 0.75 g/day once 
this target BP was achieved, the dose of RAS blocker 
(either angiotensin converting enzyme inhibitor [ACEI], 
angiotensin receptor blocker [ARB] or both) was 
increased as tolerated up to the maximum approved 
dosage. Participants were seen seven times during this 
period. In total, 34% of patients had a response to 
supportive care during this period with proteinuria 
falling to below 0.75 g/day. These responsive patients 
were excluded from the randomisation phase of the study.
Following the run-in phase, 162 participants with 
persistent proteinuria more than 0.75 g/day but less than 
3.5 g/day were randomised to the 3-year study phase. 
These participants were randomly assigned either to 
continue with maximal supportive care alone (80 
participants), or to receive maximal supportive care plus 
immunosuppressive therapy (82 participants).
Depending on the eGFR, the immunosuppression given 
in the immunosuppression arm of the study varied. 
Patients with eGFR between 30 and 59 ml/min/1.73m2 
received cyclophosphamide (1.5 mg/kg/day) for 3 
months, followed by azathioprine (1.5mg/kg/day) during 
months 4–36, plus oral prednisolone initially at dose of 
40 mg/day, tapered to 7.5 mg/day by month 6 of the 
study and continued on this dose until the study end. 
Those with eGFR of ≥60 ml/min/1.73m2 received 
glucocorticoid monotherapy for six months. They 
received intravenous methylprednisolone (1 g/day) as 
three pulsed doses at the start of months 1, 3 and 5 and 
oral prednisolone (0.5 mg/kg) every 48 hours on the 
other days.
The primary outcomes of the study were i) full clinical 
remission defined as proteinuria with a protein:creatinine 
ratio of <0.2 and stable renal function with decrease in 
the eGFR of <5 ml/min/1.73m2 from the baseline eGFR at 
the end of the 3 year trial phase and ii) a decrease in the 
eGFR of at least 15 ml/min/1.73m2 from baseline eGFR.
After three years, 14 participants in the 
immunosuppression group met the first primary 
outcome measure of full clinical remission, compared to 
only four participants in the supportive therapy alone 
group. This difference was statistically significant (p = 
0.01). However, participants who had a full clinical 
remission had lower baseline levels of proteinuria than 
those who did not. There was no statistical difference in 
the number of patients in each group with a decrease in 
eGFR of at least 15 ml/min/1.73m2 (28% in the supportive 
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care group vs 26% in the immunosuppression group) 
with no significant difference in the rate of decline of 
eGFR between groups.
There were more episodes of infection (including one 
fatal pneumonia) in the immunosuppression group, of 
which 25% were considered directly related to 
immunosuppression. There were also more episodes of 
neoplasia, impaired glucose metabolism and bodyweight 
gain in the immunosuppression arm.
The investigators stated, ‘We could not confirm our 
hypothesis that additional immunosuppressive therapy 
would provide substantial kidney-related benefits in 
patients with high risk IgAN.’ 
oPinion
IgAN is the most common primary glomerulonephritis 
in the world (including Scotland).1 Approximately one 
quarter of individuals diagnosed with IgAN with 
significant proteinuria will progress to end stage renal 
disease requiring dialysis or a kidney transplant within 
20–25 years of presentation.1 The prognosis is worse for 
those patients with persistent proteinuria.1–3 In this 
group, approximately 50% may reach end stage renal 
disease within 10 years.3 RAS blockade to aggressively 
control BP and reduce proteinuria is the mainstay of 
treatment. Current Kidney Disease: Improving Global 
Outcomes (KDIGO) guidelines also recommend use of 
immunosuppression with glucocorticoids if proteinuria 
remains above 1 g/day with maximally tolerated RAS 
blockade.4 However, with the exception of those with 
nephrotic range proteinuria (>3.5 g/day),5 the evidence 
base behind this strategy is relatively weak.6 The STOP-
IgAN trial addresses this area of uncertainty.7
The first piece of knowledge we gain from this study is 
that immunosuppression in patients with stage 1–3 
chronic kidney disease caused by IgAN without nephrotic 
range proteinuria is of very limited benefit when added 
to maximal supportive therapy.7 Previous studies, which 
inform the KDIGO guidelines, have shown some benefit 
from immunosuppressive therapy.4,8–12 However, as the 
STOP-IgAN investigators highlight, these studies lacked 
a run-in period where RAS blockade was maximised, and 
RAS blockade was either temporarily stopped pre-
baseline or was inconsistent throughout the studies.6–12 
Further questions remain unanswered about immuno-
suppression in IgAN. First, the follow up in STOP-IgAN 
was too short to determine if there is longer-term 
benefit gained from remission of proteinuria, which was 
achieved in a greater proportion of patients treated with 
immunosuppression.7 Second, due to the indolent yet 
progressive nature of IgAN, patients present at different 
stages in the disease. Some patients may have had 
haematoproteinuria for years prior to diagnosis. For 
immunosuppression to be effective there should be 
minimal irreversible renal fibrosis present. Finally, the 
individual subgroups treated with the various 
immunosuppressive regimens were small.7 It is also 
unclear if more specific future immunosuppressive 
regimes (e.g. blisibimod, spleen tyrosine kinase inhibition) 
in the era of ‘precision medicine’ may be more effective 
than the broad based immunosuppressive regimens 
employed in STOP-IgAN. The experience of STOP-IgAN 
highlights the challenges of testing new therapies in IgAN.
Perhaps the real success of this trial is the demonstration 
that traditional supportive therapy for IgAN is effective 
in the medium term – 34% of participants in STOP-IgAN 
achieved significant reduction in proteinuria.7 With 
effective RAS blockade and BP control, proteinuria can 
be reduced significantly. Furthermore, with reduction in 
proteinuria one can expect an improved longer-term 
prognosis with slower rate of decline of eGFR.7,13 
Remarkably, mean BP in STOP-IgAN was 126/78 mmHg.7 
The investigators must be commended on this 
achievement; unfortunately real life rarely replicates the 
controlled environment of a clinical trial. This trial7 does 
provide further evidence that we should be aggressively 
pursuing lower BP targets and maximising RAS blockade 
to reduce proteinuria even if, or when, these BP targets 
are achieved.
It is notable that approximately 42% of randomised 
participants in STOP-IgAN received both ARB and ACEI 
therapy simultaneously.7 Subsequent to three recent 
trials,14–16 the UK Medicines and Healthcare products 
Regulatory Agency (MHRA) issued a warning against this 
combination, because of increased risk of hyperkalaemia, 
hypotension and impaired renal function.17 STOP-IgAN 
had only one serious adverse event (in the supportive 
arm) associated with increased serum creatinine and 
potassium.7 The lack of serious complications of 
simultaneous ARB and ACEI in STOP-IgAN is probably 
due to intensive study monitoring. In clinical practice, 
where this level of monitoring is impractical, clinicians 
pursuing dual RAS blockade in this patient group would 
be contravening MHRA advice. We recommend maximal 
single-agent RAS blockade while heeding MHRA guidance.
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